Danish millionaire René Sindlev's US-based biotech company Enochian Biosciences ends another accounting period with a deficit. The coffers were filled earlier this year, but now the company has DKK 88 million (approximately USD 13.5 million) left for the pursuit of a cure for HIV.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.